Blood

Vol. 146, Issue Supplement 1 Issue Supplement 1 2025
8248
Articles

Articles in this Issue

Venetoclax in combination with dasatinib, prednisone, rituximab and blinatumomab for the upfront treatment of adults with Philadelphia chromosome positive acute lymphoblastic leukemia (Ph+ ALL), Results from a Phase 1B study

Jessica Leonard, Andy Kaempf, Curtis Lachowiez et al. Nov 03, 2025 pp. 3354-3354 10.1182/blood-2025-3354

Abstract Introduction: The second-generation ABL tyrosine kinase inhibitor (TKI) dasatinib (Das) has shown impressive re...

Integrated multidisciplinary approaches to improve prognosis prediction in multiple myeloma

Claudio Cerchione, Nour Alassi, Sarah Tassinari et al. Nov 03, 2025 pp. 2140-2140 10.1182/blood-2025-2140

Abstract Introduction: Despite the therapeutic advancements in the treatment of multiple myeloma (MM) a subset of patients shows dismal prog...

Racial disparities in lymphoma: Meta-analytic insights into diagnosis and survival gaps

Hanzala Jehangir, Muhammad Arham, Muhammad Uzair et al. Nov 03, 2025 pp. 8054-8054 10.1182/blood-2025-8054

Abstract Introduction: Lymphomas constitute a biologically heterogeneous group of clonal lymphocytic proliferations and account for approxim...

Ivosidenib in refractory or relapsed IDH1-mutated Acute Myeloid Leukemia patients in real life settings: The ivoobs observational study from the french AML intergroup ALFA/filo

Maël Heiblig, Pierre Peterlin, Stéphane Morisset et al. Nov 03, 2025 pp. 3455-3455 10.1182/blood-2025-3455

Abstract Background IDH1 R132 mutations are found in about 5-10% of AML at diagnosis. Ivosidenib (IVO) is an oral, targeted, small-molecule i...

Immunophenotypic and cytokine profiling reveal robust immunomodulation after dasatinib treatment and identify a subgroup with rapid and deep molecular response in CML patients: A multi-center prospective study

Shih-Feng Cho, Tsai-Yun Chen, Ying-Chung Hong et al. Nov 03, 2025 pp. 1975-1975 10.1182/blood-2025-1975

Abstract This multicenter prospective study aimed to evaluate the immunophenotypic and cytokine profiles of newly diagnosed chronic myeloid...

The core role of exosomal mir-21-5p/TGF-β1-CXCL12/RANKL axis in bone marrow microenvironment remodeling in multiple myeloma and targeted intervention strategies

Li Wang, AoShuang Huang, JiShi Wang Nov 03, 2025 pp. 2167-2167 10.1182/blood-2025-2167

Abstract Multiple myeloma (MM) drug resistance and bone disease are closely associated with the remodeling of the bone marrow microenvironme...

New class of dual agonistic T-cell engagers for the in-patient activation and expansion of v delta 1 T cells with broad antigen agnostic antitumour activity

Andre Simoes, Jarek Juraszek, Giulio Bocconcelli et al. Nov 03, 2025 pp. 6105-6105 10.1182/blood-2025-6105

Abstract Introduction: Gamma Delta (γδ) T cells have gained broad scientific recognition as a third subset of lymphocyte...

Transition readiness assessment in patients with bleeding disorders at Arkansas center for bleeding disorders

Divyaswathi Citla Sridhar, Kara Burge, Shelley Crary Nov 03, 2025 pp. 4396-4396 10.1182/blood-2025-4396

Abstract Background: Transitioning adolescents and young adults (AYA) with bleeding disorders to adult care is a critical process that is of...

Integrating EVI1 expression into prognostic models for MDS: Insights from IPSS-R and IPSS-m subgroup analyses

Xiaohang Ma, Wen-Bing Duan, Qi Chen et al. Nov 03, 2025 pp. 3479-3479 10.1182/blood-2025-3479

Abstract Background: EVI1 is frequently overexpressed in acute myeloid leukemia (AML) and associated with poor prognosis. Although MDS patien...

Targeting the compass complex to overcome resistance in KMT2A-rearranged Acute Myeloid Leukemia

Sandhya Dhiman, Vikramjit Dhillon, Jeff Justin Aguilar et al. Nov 03, 2025 pp. 1517-1517 10.1182/blood-2025-1517

Abstract Introduction Regulation of gene expression by histone modification is critical in drug resistance and progression. KMT2A-rearranged...

Impact of holding therapy prior to apheresis on outcomes following CD19 CAR-T cell therapy in large B-cell lymphoma

Marina Gomez-Llobell, Sarah Samorodnitsky, Silvia Escribano Serrat et al. Nov 03, 2025 pp. 6328-6328 10.1182/blood-2025-6328

Abstract Background: Patients with relapsed or refractory large B-cell lymphoma (LBCL) often experience delays between CAR-T decision and le...

Structure-based virtual screening was performed to investigate the mechanism of action of dual-target inhibitors against FMS-like tyrosine kinase 3 (FLT3) and histone deacetylase 8 (HDAC8) in leukemia

Xiaotian Yang, Ye Hong, Xingxia Zhang et al. Nov 03, 2025 pp. 6792-6792 10.1182/blood-2025-6792

Abstract ObjectiveThe aim of this study was to identify dual-target inhibitors of FMS-like tyrosine kinase 3 (FLT3) and histone deacetylase...

Sex-based differences in sepsis-related complications and mortality among hospitalized patients with Myelodysplastic Syndromes: A national inpatient sample analysis (2016–2022)

Sooraj Srirangadhamu Gopu, Jatin Thukral, Amanda Lussier et al. Nov 03, 2025 pp. 7383-7383 10.1182/blood-2025-7383

Abstract Background: Patients with myelodysplastic syndromes (MDS) are highly susceptible to infections, with sepsis being a major cause of...

Critical platelet shortages and a single Institution's experience with split platelet transfusions: Can you get by with just half a unit?

anup kumar Trikannad, Manpreet Saini, Bhavesh Mohan Lal et al. Nov 03, 2025 pp. 4924-4924 10.1182/blood-2025-4924

Abstract Introduction Blood product shortages have been a growing problem for hospital systems in the post-pandemic era. Our institution beg...

Treatment patterns and real-world effectiveness in patients with Relapsed/Refractory multiple myeloma (RRMM) and lenalidomide-exposure who received 1 to 3 prior lines of therapy

Shiyin Jiao, Jiawen Chen, Rajesh Kamalakar et al. Nov 03, 2025 pp. 4565-4565 10.1182/blood-2025-4565

Abstract Introduction: While multiple myeloma (MM) remains incurable, proteasome inhibitors, immunomodulatory drugs, anti-CD38 monoclonal an...

Hereditary spherocytic pyropoikilocytosis: Expanding the clinical and genetic spectrum of red blood cell membrane disorders

Athina Ntoumaziou, Ammar Husami, Mary Risinger et al. Nov 03, 2025 pp. 4667-4667 10.1182/blood-2025-4667

Abstract Red blood cell (RBC) membrane disorders are a phenotypically and genetically heterogeneous group, leading to hemolytic anemia of va...

Cost comparison of prophylactic vs. on-demand use of a 1:1 ratio pdVWF/FVIII concentrate in type 3 von willebrand disease with severe bleeding phenotype in the United States: A payer and societal perspective

Robert Sidonio, Jr., Nathan Connell, Fernando Corrales-Medina et al. Nov 03, 2025 pp. 1289-1289 10.1182/blood-2025-1289

Abstract Background Long-term prophylaxis with von Willebrand factor (VWF) concentrate is recommended for patients with...

Hospital bed size and sepsis-related complications in patients with Myelodysplastic Syndromes: Insights from the national inpatient sample (2016–2022)

Jatin Thukral, Sooraj Srirangadhamu Gopu, Salman Ayub Jajja et al. Nov 03, 2025 pp. 8197-8197 10.1182/blood-2025-8197

Abstract Background: Patients with myelodysplastic syndromes (MDS) are at heightened risk for severe infections, including sepsis, due to un...

Advanced myelofibrosis is marked by loss of NKG2D and DNAM-1 NK activating signaling and increased TIM-3 T CD8 exhaustion

Mariana Medeiros, Camila Garcia, Larissa Sarri Binelli et al. Nov 03, 2025 pp. 1980-1980 10.1182/blood-2025-1980

Abstract Myelofibrosis (MF), driven by JAK/STAT signaling mutations in hematopoietic stem cells, presents the worst prognosis among myelopro...

Divergence in post-traumatic stress disorder status between children receiving hematopoietic stem cell transplantation and their primary caregivers

Jiali Ma, Lijuan Liu, Jing Yao et al. Nov 03, 2025 pp. 4268-4268 10.1182/blood-2025-4268

Abstract Background and Aims: Hematopoietic Stem Cell Transplantation(HSCT) has become a cornerstone therapy for pediatric hematological dis...

Erythrocyte aggregability as a hemodynamic marker in paroxysmal atrial fibrillation

Joshua Annamalai, Kushal Kriplani, Dilan Sathi prakasan et al. Nov 03, 2025 pp. 6647-6647 10.1182/blood-2025-6647

Abstract INTRODUCTION Atrial fibrillation (AF) is the most common sustained cardiac arrhythmia and is associated with significant morbidity...

Avatrombopag: Beyond the technical sheet - a single-center experience

Manuel Rodriguez Lopez, Laura Iglesias Dominguez, Antia Amoedo Bastos et al. Nov 03, 2025 pp. 6593-6593 10.1182/blood-2025-6593

Abstract Introduction Avatrombopag, a 2nd-generation thrombopoietin receptor agonist (TPO-RA), is approved for chronic immune thrombocytopen...

Less‑intensive therapy in newly diagnosed acute myeloid leuekmia (AML) in India: Real-world adoption and prognostic utility of ELN‑LI and ELN‑2022 classification

Chepsy Philip, Uday Kulkarni, Smita Kayal et al. Nov 03, 2025 pp. 2829-2829 10.1182/blood-2025-2829

Abstract Treatment of AML in India remains challenging. Delivery of intensive chemotherapy (IC) is constrained by costs and health system fa...

Clinical and economic burden of cytokine release syndrome in a nationally representative cohort of patients receiving CAR-t therapy

Mariana Marrero Castillo, Benedict Amalraj, Anil Ananthaneni et al. Nov 03, 2025 pp. 2705-2705 10.1182/blood-2025-2705

Abstract Introduction: Chimeric antigen receptor (CAR) T-cell therapy has emerged as an effective option for several hematologic malignancie...

Efficacy of 2nd-line treatment in CLL after venetoclax-based 1st-line treatment: Results from the GAIA/CLL13 trial

Carsten Niemann, Moritz Fürstenau, Can Zhang et al. Nov 03, 2025 pp. 795-795 10.1182/blood-2025-795

Abstract Background: Data on 2nd line treatment outcome for chronic lymphocytic leukemia (CLL) after initial venetoclax-...

All Issues

Journal Info

Publisher Elsevier BV
ISSN 0006-4971
E-ISSN 1528-0020
Subject Health Sciences
Language English
View Full Journal Page